noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Kirkland & Ellis LLP

Private Equity/M&A Partner Adam Prince Joins Kirkland & Ellis
Oakland University

Natalie Ishioka named Student of the Year by the Great Lakes Affiliate[...]
ImmuCell Corporation

2025 Form 10-K (proofs 0000811641 118730 ALL DOCS clean pn120)

Healthcare

Pappas Capital LLC

03/24/2009 | Press release | Archived content

Anthera to continue impacts trial for the prevention of acute che...

News | 03. 24. 2009

Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data from the first cohort of 30 patients, an independent Data Safety Monitoring Board (DSMB) has recommended that Anthera's Phase II clinical trial, known as the IMPACTS (Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome) Study can continue under the current protocol based on favorable interim results.

Pappas Capital LLC published this content on March 24, 2009, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:09 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format